D-0311-2020 Class II Terminated

Recalled by Novitium Pharma LLC — East Windsor, NJ

FDA drug recall D-0311-2020 was initiated by Novitium Pharma LLC on Oct 25, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product. The recall status is terminated (terminated Mar 17, 2021). Affected quantity: 2718 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 20, 2019
Initiation Date
Oct 25, 2019
Termination Date
Mar 17, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2718 bottles

Product description

Novitium Pharma Ranitidine Capsules 150 mg 500 capsules Rx Only Manufactured by: Novitium Pharma LLC 70 Lake Drive, East Windsor, New Jersey 08520 NDC 70954-001-40

Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Distribution pattern

Nationwide

Code information

all lots within expiry.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0311-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0311-2020. Report a data issue: hello@regdatalab.com.